Biosourced Au(III) Complexes from D-Xylose: Synthesis and Biological Evaluation.

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2024-10-21 DOI:10.1002/cmdc.202400565

Laura M H Pascual, Jérôme Devy, Marius Colin, Lise Chazée, Alexandra Guillaneuf, Béatrice Marin, Richard Plantier-Royon, Sylvain Gatard

引用次数: 0

Abstract

A series of xylose-based ligands was obtained using a convenient approach, in a few steps from D-xylose. The complexation properties of these ligands towards Au3+ cations have been studied through different methods (multinuclear NMR, mass spectrometry, elemental analysis). The biological properties (antibacterial and anti-tumoral) of all the isolated xyloside Au(III) complexes were investigated in vitro. The xyloside Au(III) complexes gave the highest activities against E. coli(vs P. aeruginosa, S. aureus and S. epidermidis). The study also revealed that the nature of the sugar may play an important role in determining the selectivity of the antibacterial effect. Preliminary anti-tumoral evaluations showed that one complex containing a polyamine chain, exhibited interesting anti-proliferative activities on breast tumor cell lines MDA-MB-231 and BT-20. The anti-migratory effect of this complex also showed an average 35% reduction in cell migration on the same two cancer cell lines.

查看原文本刊更多论文

来自 D-木糖的生物源 Au（III）配合物：合成与生物学评价。

我们采用一种简便的方法，通过几个步骤从 D-木糖中获得了一系列基于木糖的配体。通过不同的方法（多核核磁共振、质谱、元素分析）研究了这些配体与 Au3+ 阳离子的络合特性。对所有分离出的木糖苷 Au（III）配合物的生物特性（抗菌和抗肿瘤）进行了体外研究。木糖苷 Au（III）配合物对大肠杆菌（与绿脓杆菌、金黄色葡萄球菌和表皮葡萄球菌相比）的活性最高。研究还发现，糖的性质可能在决定抗菌效果的选择性方面起着重要作用。初步抗肿瘤评估显示，一种含有多胺链的复合物对乳腺肿瘤细胞株 MDA-MB-231 和 BT-20 具有有趣的抗增殖活性。这种复合物的抗迁移效果还显示，这两种癌细胞株的细胞迁移率平均降低了 35%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.